View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Thijs Berkelder
  • Thijs Berkelder
Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thomas Couvreur
  • Wim Lewi
Lynn Hautekeete
  • Lynn Hautekeete

Home Invest Belgium FY25: Strong Underlying Performance Overshadowed b...

Home Invest reports results in line with our expectations at €1,21 EPRA EPS. It guides €1,23 EPRA EPS in FY26, slightly ahead of our expectation of € 1,20. At 1H25 results, Home Invest confirmed our thesis that the building right in Louvain-La-Neuve will not get renewed. As of the announcement Home Invest started to underperform (-7,1%) the EPRA index (+8,6%). The UCL has time until June 2026 to respond. This headwind will keep EPRA EPS growth muted, despite the stellar operational results: 98,...

 PRESS RELEASE

Galapagos Receives Transparency Notifications from Bank of America

Galapagos Receives Transparency Notifications from Bank of America Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 5, 6, and 9, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos’ voting rights on February 2, 2026, followed by its controlle...

 PRESS RELEASE

Galapagos ontvangt transparantieverklaringen van Bank of America  

Galapagos ontvangt transparantieverklaringen van Bank of America   Mechelen, België; 10 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Galapagos op 5, 6 en 9 februari 2026 transparantieverklaringen van Bank of America Corporation. Daaruit blijkt dat Bank of America Corporation, als controlerende entiteit, op 2 februari 2026 de drempel van 5% van de stemrechten van Galapagos heeft overschreden, gevolgd door haar gecontro...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Serbia regulation to be litigated at international level. CM.com: Preview FY25. dsm-firmenich: At last! Exor: Stellantis shares fall sharply on €22bn turnaround plan, writeoff. Euronext: 2026 starting strong. Proximus: €275m impairment at Proximus Global

Martijn Den Drijver
  • Martijn Den Drijver
 PRESS RELEASE

Euronext announces volumes for January 2026

Euronext announces volumes for January 2026 Euronext announces volumes for January 2026 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 February 2026 – Euronext, the leading European capital market infrastructure, today announced trading volumes for January 2026. Monthly and historical volume tables are available at this address: CONTACTS   ANALYSTS & INVESTORS – Investor Relations        Judith Stein         97         Margaux Kurver         03         MEDIA –   Europe        Andrea Monzani          13          Sandra Machado         7 Belgium        M...

 PRESS RELEASE

Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...

Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...

 PRESS RELEASE

Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2...

Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026  Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...

 PRESS RELEASE

Euronext completes €250 million share repurchase programme

Euronext completes €250 million share repurchase programme Euronext completes €250 million share repurchase programme Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 29 January 2026 – Euronext today announced that it has completed the share repurchase programme announced on 6 November 2025. Between 18 November 2025 and 27 January 2026, 1,967,993 shares, or approximately 1.90% of Euronext’s share capital, were repurchased at an average price of €127.03 per share. This repurchase programme was executed by a financial intermediary in compliance with applicable rules and ...

 PRESS RELEASE

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvre...

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité de la société Inventiva concl...

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 26 janvier 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique ("MASH"), annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de liquidité portant sur les actions de la Société confié à Kepler Cheuvreux,...

Stijn Demeester
  • Stijn Demeester

Umicore/Metals prices melt-up drives earnings upgrade/HOLD

We raise our 2025F-26F estimates for Umicore on the back of higher precious and platinum group metals prices, with our estimates for the battery materials business broadly unchanged. We raise our target price from €10 to €19 per share, driven by higher estimates and peer multiples, yet maintain our HOLD recommendation. Umicore shares have rallied +85% over the last year, largely driven by the melt-up in metals prices, although its earnings power in 2026F is likely moderated by elevated hedging l...

Umicore S.A.: 1 director

A director at Umicore S.A. bought 1,000 shares at 18.460EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch